NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa.
In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.
NanoViricides believes the drug could address multiple unmet medical needs, including influenza, RSV, measles, monkeypox, and smallpox.
During the quarter, the company continued preparations for a Phase II trial in the Democratic Republic of Congo, which has received conditional approval from local regulators.
NanoViricides plans to seek orphan drug designations for NV-387 for monkeypox, smallpox, and measles, which could provide market exclusivity, tax credits, and expedited FDA interactions.
Financially, the company reported $1.25 million in cash and cash equivalents as of September 30, with total assets of $8.36 million and current liabilities of $1.18 million.
NanoViricides raised roughly $6.1 million in recent registered direct and private placement offerings, in addition to ongoing access to a $3 million line of credit from founder and president Dr Anil Diwan.
The company said additional financing, including potential warrant exercises, will be required to fund planned Phase II trials for monkeypox and respiratory infections, as well as pre-IND preparation for RSV.
Shares of NanoViricides rose around 5.5% on Monday morning in New York.